Unseen 13

More than 13% of patients (1 in 8) with NSCLC
have the KRAS G12C  mutation, yet too many go undetected.1,2 Identifying these patients and learning more about this prevalent mutation is a high priority.

For more information,
contact Amgen Medical Information.

KRAS, Kirsten rat sarcoma; NSCLC, non-small cell lung cancer.

References: 1. Biernacka A, Tsongalis PD, Peterson JD, et al. Cancer Genet. 2016;209:195-198. 2. Gutierrez ME, Choi K, Lanman RB, et al. Clin Lung Cancer. 2017;18:651-659.